What Is Value in Health Care?

Porter, Michael E.

doi:10.1056/nejmp1011024

Cited by 4,119 publications

(3,384 citation statements)

References 0 publications

Supporting

Mentioning

3,169

Contrasting

Unclassified

Order By: Relevance

“…In doing so, it enables continuous assessment over the entire course of the disease in alignment with the fundamental framework of value‐based health care delivery 51. Although this approach may currently present an implementation challenge, we hope it stimulates providers from different settings to coordinate their activities around the patient as opposed to conducting isolated interventions, creating consistency over the full continuum of care.…”

Section: Discussionmentioning

confidence: 99%

Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group

Rolfson

Wissig²,

Maasakkers³

et al. 2016

Arthritis Care & Research

122

View full text Add to dashboard Cite

ObjectiveTo define a minimum Standard Set of outcome measures and case‐mix factors for monitoring, comparing, and improving health care for patients with clinically diagnosed hip or knee osteoarthritis (OA), with a focus on defining the outcomes that matter most to patients.MethodsAn international working group of patients, arthroplasty register experts, orthopedic surgeons, primary care physicians, rheumatologists, and physiotherapists representing 10 countries was assembled to review existing literature and practices for assessing outcomes of pharmacologic and nonpharmacologic OA therapies, including surgery. A series of 8 teleconferences, incorporating a modified Delphi process, were held to reach consensus.ResultsThe working group reached consensus on a concise set of outcome measures to evaluate patients’ joint pain, physical functioning, health‐related quality of life, work status, mortality, reoperations, readmissions, and overall satisfaction with treatment result. To support analysis of these outcome measures, pertinent baseline characteristics and risk factor metrics were defined. Annual outcome measurement is recommended for all patients.ConclusionWe have defined a Standard Set of outcome measures for monitoring the care of people with clinically diagnosed hip or knee OA that is appropriate for use across all treatment and care settings. We believe this Standard Set provides meaningful, comparable, and easy to interpret measures ready to implement in clinics and/or registries globally. We view this set as an initial step that, when combined with cost data, will facilitate value‐based health care improvements in the treatment of hip and knee OA.

show abstract

Section: Discussionmentioning

confidence: 99%

Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group

Rolfson

Wissig²,

Maasakkers³

et al. 2016

Arthritis Care & Research

122

View full text Add to dashboard Cite

show abstract

“…Treatment evaluation also often stops when medical attention is no longer needed, thus missing any post-treatment period of residual impairment before full recovery. Furthermore, medically administered therapeutic interventions do not affect mild disease episodes for which medical attention is not sought [33]. Thus, medical treatment addresses only part of the total disease burden, although as it is the part most immediately obvious to the patient, it is the simplest part to recognise and to measure.…”

Section: Differences Between Vaccines and Therapeutic Drugsmentioning

confidence: 99%

Towards a more comprehensive approach for a total economic assessment of vaccines?

Standaert

Rappuoli²

2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

ABSTRACTSince we were born, we all take preventative actions to avoid unpredictable adverse conditions. Some actions are done automatically. Others require a conscious choice , either for personal or social benefit. A distinction can therefore be drawn between non-active and active prevention, and between individual and social prevention. Active prevention requires making a choice in time, effort, and cost. We call it an economic choice. Vaccines belong to the group of active and social prevention. Because a vaccination program is an economic social choice, how should it be valued, and what cost should we pay for? To date, the economic evaluations developed for treatment have been applied to vaccines. However, over 25 different characteristics differentiate vaccines from treatment. For example, the benefit of vaccination is measured at the population level not at the individual level, the main effect of prevention is societal and not an individual-based gain only, and the biggest hurdle to implement a new vaccine is the initial budget investment and not so much its estimated ‘value for money’. This makes the current application of incremental cost-utility analysis difficult for vaccines for a comprehensive evaluation. New approaches may be needed to capture the full economic benefit of vaccines.

show abstract

“…15,20 Patient adherence is a crucial link between care process and health outcomes. 1 Although the effect of recommendation adherence on medical outcomes has not been previously studied in the field of general pediatric genetics, the effect of adherence to medications and treatments in other fields has been shown to reduce the effects of disease. The use of medical outcomes studied and accepted in other areas of health care may help demonstrate the value of genetic counseling to payers and employers.…”

Section: Medical Management Adherencementioning

confidence: 99%

“…Value in health care, defined as health outcomes achieved per dollar spent, benefits patients, payers, and providers by providing the best patient care while maintaining cost efficiency. 1 Evidence-based genetic counseling is important to maximizing health outcomes for patients and for the maturity of the profession, so that entities inside and outside the profession have a clear understanding of the goals and expected outcomes of genetic counseling practice. Entities outside the profession, such as state licensing boards, insurance companies, and other health-care providers, may use outcome studies to justify the hiring and reimbursement of GCs.…”

Section: Introductionmentioning

confidence: 99%

“…2 Patient adherence is a crucial link between the process of providing health-care and health outcomes. 1 Medical management adherence is widely studied in medicine. Factors affecting adherence to medication are multifactorial and include patient-related factors (e.g., age and cognitive impairment), condition-related factors (e.g., severity and type of symptoms), socioeconomic factors (e.g., high treatment costs and low literacy), therapy-related factors (e.g., complexity of the regimen), and health-system factors (e.g., access to healthcare).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medical management adherence as an outcome of genetic counseling in a pediatric setting

Rutherford

Zhang

Atzinger

et al. 2014

Genetics in Medicine

View full text Add to dashboard Cite

What Is Value in Health Care?

Cited by 4,119 publications

References 0 publications

Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group

Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group

Towards a more comprehensive approach for a total economic assessment of vaccines?

Medical management adherence as an outcome of genetic counseling in a pediatric setting

Contact Info

Product

Resources

About